
INAUGURAL EATRIS CONFERENCE



3RD AND 4TH JUNE 2013
AMSTERDAM, THE NETHERLANDS



WELCOME

Dear Colleagues and Guests,

On behalf of my co-director Frank de Man, and the whole team at EATRIS, I am honoured to welcome you to this meeting, celebrating the inauguration of operations for EATRIS. This is an important milestone for EATRIS, as we move forward following a lengthy construction process and are now free to focus on adding value in the scientific and healthcare arena.

As you know, the complexity of translational medicine and innovation is increasing. Efficient access to the broad array of advanced technologies and know-how in the field is becoming increasingly difficult for a single institution. Our distributed infrastructure is young and growing but already has the capacity to serve the needs of our stakeholders through the provision of an extensive range of translational research services and expertise for high potential projects.

We feel that this initiative is a crucial step forward for the European Union. It allows Member States to avoid infrastructure duplications, and facilitates more efficient use of the available resources in these scientifically and economically challenging times.

However, EATRIS is not only a service provider but is also a team of scientists who aim to improve outcomes in translational medicine and to challenge the current paradigms of therapeutic and diagnostic development. Science is also a social endeavour and as scientists it is our responsibility to serve present and future generations to the best of our ability. In the end we, like yourselves, are committed to finding solutions to some of the primary societal challenges of our time.

An exciting number of issues are on our agenda for discussion during this meeting. We wish to provide you with an informative and stimulating event. And finally we hope that, with your involvement, EATRIS will become a valuable partner in facilitating and energising translational research in Europe, and ultimately bringing substantial benefit to patients the world over. Together we can achieve this.

Giovanni Migliaccio,
Scientific Director, EATRIS

MONDAY 3RD JUNE 2013

PROGRAMME

11:30 – 13:25

The current translational research landscape

- 11:30 – 12:30 Registration and lunch
- 12:30 – 12:45 Welcome
Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands
- 12:45 – 13:05 Translational research concepts
— the need to close the gap
Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands
- 13:05 – 13:25 Goal-directed collaboration: How EATRIS works
Anton Ussi, M.Sc. Amsterdam, The Netherlands
-

13:25 – 16:00

**Serving Europe's needs in translational research
and alleviating the bottlenecks**
Chair: Marcel Levi

- 13:25 – 13:50 Translational Medicine and Advanced Therapy
Medicinal Products
Maria Cristina Galli, Ph.D. Rome, Italy
- 13:50 – 14:15 Translational Medicine and Biomarkers
Olli Kallioniemi, MD. Ph.D. Helsinki, Finland
- 14:15 – 14:40 Translational Medicine and Imaging and Tracing
Guus van Dongen, Ph.D. Amsterdam, The Netherlands
-

MONDAY 3RD JUNE 2013

- 14:40 – 15:10 Break
- 15:10 – 15:35 Translational Medicine and Small Molecules
Mario Salmona, Ph.D. Milan, Italy
- 15:35 – 16:00 Vaccine development: From bench to clinic
Jan Langermans, Ph.D. Rijswijk, The Netherlands
-

16:00 – 22:00

Round table discussion and Networking events

- 16:00 – 16:45 Round table discussion: Optimising the
yield of academic research
Marcel Levi, MD. Ph.D. Amsterdam, The Netherlands
- 16:45 – 17:00 The EATRIS umbrella and support function
Frank de Man, LL.M. Ph.D. Amsterdam, The Netherlands
- 17:00 – 19:00 Icebreaker session
- 19:00 Word of welcome
*Carolien Gehrels, Alderperson Economic Affairs,
Municipality of Amsterdam*
- 19:00 – 22:00 Walking dinner, meet and eat
-

MONDAY 3RD JUNE 2013

FACULTY



● GUUS VAN DONGEN, Ph.D.

VU University Medical Center, The Netherlands

Guus van Dongen is Professor and Head of Preclinical Imaging at the Department of Radiology and Nuclear Medicine (Tracer Center Amsterdam), and project leader of the Imaging Center Amsterdam, VUmc, The Netherlands.

He is also the Chair of the Imaging and Tracing Product Platform at EATRIS. He has a wealth of experience in molecular targeted therapy and is known for his work in “immuno-PET” and “TKI-PET”, which utilises PET imaging of radiolabeled mAbs and TKIs, and also for his research in photoimmunodetection.



● MARIA CRISTINA GALLI, Ph.D.

ISS, Italy

Maria Cristina Galli is Senior Researcher at the Istituto Superiore di Sanità (ISS), Italy. Dr Galli is the co-Chair of the ATMP Product Platform within EATRIS and, as a quality assessor and

regulatory expert for biotechnology and gene therapy in the Committee for Advanced Therapies (CAT) and Gene Therapy Working Party, brings a wealth of knowledge in the development of new technologies in this field.



● OLLI KALLIONIEMI, MD. Ph.D.

FIMM, Finland

Olli Kallioniemi is Director of the Institute for Molecular Medicine (FIMM), Finland and is Chair of the Biomarkers Product Platform within EATRIS.

He is author of over 300 publications, inventor and co-inventor of 20 issued patents, with a focus on diagnostic technology development and bioinformatics – he has a special interest in the use of translational research to improve diagnostics and therapy of leukemia.



● JAN LANGERMANS, Ph.D.
BPRC, The Netherlands

Jan Langermans is Chairman of the Animal Science Department of BPCR, The Netherlands and the Chair for the Vaccines Product Platform at EATRIS. He is an expert in vaccine development, animal studies, ethics and biosafety.



● MARCEL LEVI, MD. Ph.D.
University of Amsterdam, The Netherlands

Marcel Levi is Professor of Medicine at the University of Amsterdam and Dean of the Faculty of Medicine of the University of Amsterdam. He has published more than 700 articles in international scientific journals and brings a multidisciplinary approach to the table through his professional career as a doctor, governor, teacher and scientist.



● FRANK DE MAN, LL.M. Ph.D.
Finance Director EATRIS

Frank de Man is Finance Director of EATRIS and has extensive experience in the setting up and financing of public-private initiatives in research and healthcare.



● GIOVANNI MIGLIACCIO, Ph.D.
Scientific Director EATRIS

Giovanni Migliaccio is Scientific Director of EATRIS and an expert in the area of Cell and Gene Therapies for the European Medicines Agency (EMA) and the European Department for Quality of Medicines (EDQM).



● MARIO SALMONA, Ph.D.

Mario Negri Institute, Italy

Mario Salmona is Professor and Head of the Department of Molecular Biochemistry and Pharmacology and Head of Laboratory of Biochemistry and Protein Chemistry of The Mario Negri Institute, Italy. He is also Chair of the Small Molecules Product Platform at EATRIS. He is an expert in the field of the structural and functional studies of specific pharmacologically important gene products using the latest animal and computer simulated methods to review protein misfolding and neurodegeneration.



● ANTON USSI, M.Sc.

Head of Operations EATRIS

Anton Ussi is a specialist in the establishment and execution of strategic public-private and public-public collaborations based on the deployment of high value translational research infrastructure for medicine.

TUESDAY 4TH JUNE 2013

PROGRAMME

09:00 – 10:50

Welcome and introduction

09:00 – 10:00 Registration

10:00 – 10:10 Welcome
Marja-Liisa Niemi, Lic.Phil. Helsinki, Finland

10:10 – 10:30 An introduction to EATRIS and its members
Giovanni Migliaccio, Ph.D. Amsterdam, The Netherlands

10:30 – 10:50 Greater than the sum: making international
collaboration in translational medicine work
Anton Ussi, M.Sc. Amsterdam, The Netherlands

10:50 – 12:50

**A review of current translational research models
from a global perspective**
Chair: Marián Hajdúch

10:50 – 11:15 The Czech Republic vision on biomedical
research cooperation
Miroslava Kopicova, Prague, Czech Republic

11:15 – 11:40 Public-private partnerships and rare diseases
Philippe Froissard, Brussels, Belgium

11:40 – 12:05 Case study — A perspective from ‘Down Under’
on translating health discovery into clinical application
Stewart Hay, Ph.D. Melbourne, Australia

TUESDAY 4TH JUNE 2013

12:05 – 12:25 Case study – where East meets West
Akihiro Shimosaka, Ph.D. Tokyo, Japan

12:25 – 12:50 A review and panel discussion
Marián Hajdúch, MD. Ph.D. Olomouc, Czech Republic

12:50 – 14:00 **Inauguration EATRIS and lunch**

12:50 – 13:00 Official launch of EATRIS hosted by
Wim Stalman, MD. Ph.D. Amsterdam, The Netherlands
Edvard Beem, Ph.D. The Hague, The Netherlands

13:00 – 14:00 Lunch

14:00 – 16:00 **Exploring opportunities to close the translational research gap** ***Chair: Joan Comella***

14:00 – 14:20 The opportunities for complementarity between industry
and EATRIS
Gerd Schnorrenberg, Prof. Ph.D.
Biberach an der Riß, Germany

14:20 – 14:40 The key to successful patient participation
Buddug Cope, M.Sc. London, UK

14:40 – 15:10 The biotech SME as a risk mediator in translational research
Tom Saylor, MBA Cambridge, UK

TUESDAY 4TH JUNE 2013

- 15:10 – 15:30 The charity perspective on translational research
Gerrit Meijer, MD. Ph.D. &
Wia Timmerman, Ph.D. Amsterdam, The Netherlands
- 15:30 – 15:50 A review and panel discussion
Joan Comella, Ph.D. Barcelona, Spain
- 15:50 – 16:00 Summary and closing remarks
Maria Ferrantini, Ph.D. Rome, Italy
- 16:00 Close
-

TUESDAY 4TH JUNE 2013

FACULTY



- EDVARD BEEM, Ph.D.

The Netherlands Organisation for Health
Research and Development, The Netherlands

Edvard Beem is Co-director of the Netherlands Organisation for Health Research and Development (ZonMw), with a special interest in corporate strategy development and international relations. He has a Ph.D. in Medical Chemistry specialising in proteomics of lysosomal storage diseases. He represents The Netherlands on the EATRIS Board of Governors.



- JOAN X. COMELLA, MD. Ph.D.

University of Barcelona, Spain

Joan X. Comella is Professor of Cell Biology at the University of Barcelona (UAB) and Scientific Director of Vall d'Hebron Hospital. He leads the Spanish scientific participation in EATRIS and manages the relationship of this consortium with the ISCIII and the Spanish Ministry of Science and Innovation. Joan Comella is also the Chair of the Board of National Directors of EATRIS.



- BUDDUG COPE, M.Sc

Genetic Alliance, UK

Buddug Cope is Director of Development at Genetic Alliance UK — the national alliance of 160 patient groups, representing all those affected by genetic conditions. Genetic Alliance UK supports the acceleration of scientific and medical innovation into healthcare, improving and developing health services that deliver better patient outcomes and runs the multistakeholder campaign group Rare Disease UK.



● MARIA FERRANTINI, Ph.D.
Istituto Superiore di Sanità, Italy

Maria Ferrantini is a Senior Investigator in the Department of Haematology, Oncology and Molecular Medicine at the Istituto Superiore di Sanità (ISS), the Italian National Institute of Health.

Dr. Ferrantini has been actively involved in the preparatory phase of the ESFRI BMS research infrastructures ECRIN and EATRIS representing the Italian governmental partner. She also serves as Project Manager of the ERA-NET Translational Cancer Research TRANSCAN.



● PHILLIPE FROISSARD, Ph.D.
European Commission, Belgium

Phillipe Froissard graduated in nuclear engineering in Grenoble (France) in 1988 and completed his Ph.D. in nuclear physics in 1992. He worked on nuclear fusion research and in 2000 he joined

the Directorate-General for Research. He participated to the development and implementation of several programmes and activities in the area of mobility and International Cooperation. He is presently the Deputy Head of the Research Infrastructures Unit at the European Commission.



● MARIÁN HAJDÚCH, MD. Ph.D.
Institute of Molecular and Translational
Medicine, Czech Republic

Marián Hajdúch is Director of the Institute of Molecular and Translational Medicine (IMTM) Olomouc, Czech Republic. He is a scientist and

a medical professional mainly involved in molecular and translational medicine (disease area oncology and infectious diseases). He has been involved as principal investigator or investigator in 12 clinical trials and is actively participated in the research and/or management of more than 40 national and international projects. He has established major cancer research foundations and spin-off company focused on manufacturing of molecular diagnostic devices. He is author over 200 papers and inventor of 23 issued patents.



● STEWART HAY, Ph.D.

Therapeutic Innovation Australia, Australia

Stewart Hay is the CEO of Therapeutic Innovation Australia (TIA) which supports translational health researchers through providing world class commercial expertise and enabling access to state of the art equipment and facilities. Stewart will share some valuable insights on TIAs strategy to improve the efficiency and effectiveness of translational health research in Australia through local development of small molecule, biological, pre-clinical and clinical trial capabilities.



● GERRIT MEIJER, MD. Ph.D.

VU University Medical Center, The Netherlands

Gerrit Meijer is a Professor in pathology who leads a translational research group that focuses on gastrointestinal cancer. This involves -omics based tumour profiling, using DNA, RNA and proteomics based techniques, in order to stratify patient groups and arrive at individual tailored therapies. Furthermore, genomic and proteomics profiling of pre-malignant lesions is used for bio-marker development to improve (colorectal) cancer screening. Building infrastructure to support this translational research is another focus.



● MARJA-LIISA NIEMI, Lic.Phil.

Ministry of Education, Finland

Marja-Liisa Niemi is Counsellor for Education at the Ministry of Education and Culture and is responsible for strategic research policy development in the areas of health research and innovations (e.g. national policies, international collaboration, infra-structures, financing) in Finland. She represents the Finnish Government in the preparation of the ERIC applications of EATRIS, BBMRI and the International Consortium Agreement for ELIXIR as well as the preparation of GmbH for Infrafrontier. She is a delegate to ESFRI Health and Food Strategic Working Group. She chairs the EATRIS Board of Governors.



- THOMAS REESE SAYLOR, MBA.
Arecor Ltd. UK

Tom Saylor is an experienced CEO with a track record of building and managing entrepreneurial organisations. His experience includes fundraising, strategy development, in- and out-licensing, and acquisitions in Asia, Europe and the United

States and can provide a truly global outlook on the issues faced when bridging the translational research gap.



- GERD SCHNORRENBURG, Prof. Ph.D.
Boehringer Ingelheim Pharma GmbH & Co,
Germany

Gerd Schnorrenberg is honorary Professor of the federal state Rheinland-Pfalz in parallel with his function at Boehringer Ingelheim. He has broad experience in drug discovery and development

and manages one of the biggest research campuses within Boehringer Ingelheim, with research on cardiometabolic diseases, CNS diseases, and respiratory diseases.



- AKIHIRO SHIMOSAKA, Ph.D.
Director Research Foundation, Japan

Akihiro Shimosaka is Director at the Research Foundation for Community Medicine in Tokyo and serves as Chairman of the ISCT regulatory affairs for Asian-Pacific region. He has worked on research projects for Amgen, Genentech,

Immunex, Dendreon, Anosys, Cerus, Miltenyi, Medarex etc. and is an expert in the field of oncology, haematology and immunology.



- WIM STALMAN, MD. Ph.D.
VU University, Medical Center,
The Netherlands

Wim Stalman is Professor of General Practice at the Institute for Research in Extramural Medicine (EMGO) at the VU University Medical Center in Amsterdam and Vice President of the board of directors of the VU University Medical Center and Dean of the medical faculty.



- WIA TIMMERMAN, Ph.D.
Dutch Cancer Society, The Netherlands

Wia Timmerman is Project Leader at the Dutch Cancer Society with the remit to pursue innovation in the field of Translational Research. She is a medical biologist and has many years experience working within a Clinical Research Organisation for Phase I and Phase IIa studies. Wia Timmerman will share the current advances of translational research at the Dutch Cancer Society.

Scope of the meeting

- To discuss challenges and opportunities to bridge the innovation gap and reduce overall cost in global therapeutic and diagnostic innovation;
- To hear from international stakeholders on their needs and discuss how to jointly approach the challenges in translational medicine;
- To celebrate the inauguration of EATRIS operations as a new international organisation.

Target Audience

- Researchers from EATRIS institutions
- Researchers in translational medicine
- Delegates from Pharmaceutical industry
- SMEs
- Charities
- Research funding organisations
- Government bodies, such as regulatory authorities
- Patients' organisations

Educational Objectives


At the end of the EATRIS conference participants will:

1. Be up to date on the current international cooperation models of translational research.
2. Gain insights into the current challenges and future perspectives of academic translational research. Be informed on the current state of the art in ATMP, biomarkers, imaging and tracing, small molecules and vaccines.
3. Understand how novel public-private collaborative research models can advance translational research.
4. Know how and where to access EATRIS translational research services.



WWW.EATRIS.EU

CONFERENCE VENUE



Amsterdam RAI, Europaplein, NL
1078 GZ, Amsterdam — Hall F.

Amsterdam RAI is easy to reach by both public transport or by car and has ample parking facilities on and outside its site.

By tram, metro or bus: Tram 4 runs between the RAI (Europaplein stop), Amsterdam's city centre and Amsterdam Central Station.

We acknowledge the following organisations for their financial support:

- Ministry of Education, Youth and Sports, Czech Republic
- Ministry of Science, Innovation and Higher Education, Denmark
- Estonian Government / Ministry of Education, Estonia
- Ministry of Education & Culture, Finland
- French Alternative Energies and Atomic Energy Commission (CEA), France
- Technical and Scientific public body of the Italian National Health Service (ISS), The Istituto Superiore di Sanità, Italy
- The Organisation for Health Research and Development, The Netherlands
- Research Council of Norway, Norway
- National Institute of Health Carlos III (ISCIII), Spain
- City of Amsterdam





